Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients
María Teresa Cibeira(Boston University), Martha Skinner(Boston University), Karen Quillen(Boston University), John L. Berk(Boston University), Gheorghe Doros(Boston University), David C. Seldin(Boston University), Joan Bladé(Hospital Clínic de Barcelona), Frederick L. Ruberg(Boston University), Laura M. Dember(Boston University), Adam Segal(Boston University), J. Mark Sloan(Boston University), Kathleen T. Finn(Boston University), Nancy Andrea(Boston University), Hans K. Meier-Ewert(Boston University), Vaishali Sanchorawala(Boston Medical Center)
Cited by 288
Related Papers
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
|British Journal of Haematology|1998|1.5k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k